Jin Ho Baek1, Jong Gwang Kim1, Dong Won Baek2, Byung Woog Kang2, Soo Jung Lee2, Hye Jin Kim3, Su Yeon Park3, Jun Seok Park3, Gyu Seog Choi3. 1. Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Kyungpook National University Cancer Research Institute, Daegu, Republic of Korea wwhite71@hanmail.net jkk21c@knu.ac.kr. 2. Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Kyungpook National University Cancer Research Institute, Daegu, Republic of Korea. 3. Department of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Abstract
BACKGROUND/AIM: This study evaluated the clinical significance of the mismatch repair (MMR) status and prognostic factors in patients with high-risk stage II colon cancer (CC). MATERIALS AND METHODS: This was a retrospective analysis of 237 patients diagnosed with high-risk stage II CC who had test results for MMR status. RESULTS: Among the 237 patients, 76 (32.1%) were identified as having a microsatellite instability-high (MSI-H) status. No significant differences were identified in disease-free or overall survival according to the MMR status. Moreover, no association was found between the use of adjuvant chemotherapy and survival outcomes of the MSI-H group. In a multivariate survival analysis, the primary tumor location (right-sided versus left-sided, hazard ratio(HR)=0.172, p=0.003) and T-stage (HR=4.764, p=0.005) were identified as independent prognostic factors for disease-free survival. CONCLUSION: The present study found that the MMR status was neither prognostic nor predictive in patients with high-risk stage II CC. Copyright
BACKGROUND/AIM: This study evaluated the clinical significance of the mismatch repair (MMR) status and prognostic factors in patients with high-risk stage II colon cancer (CC). MATERIALS AND METHODS: This was a retrospective analysis of 237 patients diagnosed with high-risk stage II CC who had test results for MMR status. RESULTS: Among the 237 patients, 76 (32.1%) were identified as having a microsatellite instability-high (MSI-H) status. No significant differences were identified in disease-free or overall survival according to the MMR status. Moreover, no association was found between the use of adjuvant chemotherapy and survival outcomes of the MSI-H group. In a multivariate survival analysis, the primary tumor location (right-sided versus left-sided, hazard ratio(HR)=0.172, p=0.003) and T-stage (HR=4.764, p=0.005) were identified as independent prognostic factors for disease-free survival. CONCLUSION: The present study found that the MMR status was neither prognostic nor predictive in patients with high-risk stage II CC. Copyright
Authors: Yuting Zhang; Zehua Wu; Bin Zhang; Huabin Hu; Jianwei Zhang; Yi Chen; Miaomiao Ding; Yabing Cao; Yanhong Deng Journal: Ann Transl Med Date: 2022-06
Authors: Ning Zhao; Yinghao Cao; Jia Yang; Hang Li; Ke Wu; Jiliang Wang; Tao Peng; Kailin Cai Journal: Front Oncol Date: 2021-06-17 Impact factor: 6.244